Back

Longitudinal validation of the phospholamban (PLN) p.Arg14del risk model

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Emerging role of genetic testing for ventricular arrhythmia management Ion Channel Disorders ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Miss Myrthe Van Der Heide

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome
Professor V. Probst (Nantes, FR)
Abstract Slides Video
Presentation thumbnail
Natural History of Patients with Typical and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia
Doctor A. Trancuccio (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Calmodulinopathy is a common cause of critical cardiac phenotypes in fetus and infancy
Doctor M. Fukuyama (Otsu, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of the ICD in patients with catecholaminergic polymorphic ventricular tachycardia
Assistant Professor A. Mazzanti (Pavia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging role of genetic testing for ventricular arrhythmia management

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
A comprehensive CMR analysis improves risk stratification in left ventricular noncompaction
thumbnail
Congress Presentation
Development and internal-external validation of a prediction model for premature ventricular contraction unresponsive to the medical treatment
thumbnail
Congress Presentation
New joint model for the dynamic prediction of heart failure in phospholamban (PLN) p.(Arg14del) positive individuals

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources